Article Text

Download PDFPDF

Update on the Manchester Scoring System for BRCA1 and BRCA2 testing
  1. D G R Evans1,
  2. F Lalloo1,
  3. A Wallace1,
  4. N Rahman2
  1. 1Academic Unit of Medical Genetics, Regional Genetics Service and National Genetics Reference Laboratory, St Mary’s Hospital, Manchester M13 0JH, UK
  2. 2Section of Cancer Genetics, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
  1. Correspondence to:
 Professor D G R Evans
 University Department of Medical Genetics and Regional Genetic Service, St Mary’s Hospital, Hathersage Road, Manchester, M13 0JH, UK;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We recently published a new scoring system to estimate the chance of identifying mutations in the BRCA1 and BRCA2 genes (table 1).1 A potential criticism of the original paper was that not all cases were fully screened for mutations in both BRCA1 and BRCA2. We have now extended our analyses to address this. In total, we have screened 921 samples from familial breast cancer pedigrees from the Manchester region through the whole coding sequence and intron/exons boundaries of both genes. In addition, 200 cases, with all cases with a Manchester combined score for BRCA1 and BRCA2 of 40 or above, were screened for exonic deletions/duplications by multiplex ligation dependent probe amplification (MLPA). These analyses resulted in the identification of 206 (22.5%) intragenic mutations and nine (4.5%) exonic deletions or duplications (tables 2 and 3).

Table 1

 Manchester scoring system

Table 2

 Proportion of families with pathogenic mutations for each Manchester score range

Table 3

 Proportion with mutations using the combined BRCA1/2 score

Table 2 shows that the 10 point Manchester score for a 10% threshold for each gene holds up well. The results for BRCA1 are presented with and without BRCA2 positive families with male breast cancer. Similarly, the results for BRCA2 are presented with and without BRCA1 positive families with ovarian cancer. These data allow one to estimate the likelihood of identifying a mutation in the gene screened second. For example, a breast/ovarian cancer family with a score of 28 for BRCA1 and 22 for BRCA2 has a 58% chance (column 3, table 2) of harbouring a BRCA1 mutation. If BRCA1 screening in the family is negative, the chance of identifying a BRCA2 mutation is 57% (column 5, table 2). The overall chance of a BRCA2 mutation in such a family prior to testing BRCA1 is therefore 24% (57% of 42%, the remainder of 100%–58%). The overall chance of a mutation in either gene is 82% (58%+24%). A similar process could be undertaken for families with male breast cancer.

As can be seen from table 3, a combined Manchester score of 15 is the cut off for a 10% threshold for BRCA1/2 testing. The cut off for a 20% threshold is less clear. Families with scores >20 would definitely qualify and those with scores of 17 points or above could reasonably be tested. It can be assumed that virtually all families with scores of 40 or above are due to either BRCA1 or BRCA2, although not all will have identifiable BRCA1/2 abnormalities as the sensitivity of gene testing is not 100% even with full gene screening and MLPA.2 Moreover, the pathogenicity of unclassified variants (which were not included in our analyses) remains unclear.



  • Competing interests: none declared